Pulmonary Disease, Chronic ObstructiveNCT05616780
Does Severity of Airflow Obstruction Correlate to Static Lung Volumes
A study testing Physiological test in people with Pulmonary Disease, Chronic Obstructive, run by Virginia Hawkins at 1 site in United Kingdom.
Trial summary
Obstructive lung disease is defined by limitations in expiratory airflow, caused by excess mucus, loss of muscle tone, and structural changes. Over time airflow reduction can lead to gas trapping in the lungs (hyperinflation). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pulmonary Disease, Chronic Obstructive
- What is being tested?
- Physiological test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 16 Mar 2023to 31 May 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- A minimum of 10 patients from each group will be included; normal lung function/ no airflow obstruction (FEV1/FVC >70%), mild airflow obstruction (FEV1/FVC <70% and FEV1 >80% predicted), moderate airflow obstruction (FEV1/FVC <70% and FEV1 50-80% predicted), severe airflow obstruction (FEV1/FVC <70% and FEV1 30-50% predicted) and very severe (FEV1/FVC <70% and FEV1 >30% predicted).
- Al patients will be over the age of 18 with no upper age limit. No children will be included in this study.
- Patients must have withheld their inhalers.
Who cannot join
- [15:10] Jessica Armstrong
- Contraindications to performing the test include (if occurred within last 8 weeks):
- Heart attack
- Stroke
- Haemoptysis
- Pneumothorax
Show all 23Show fewer
- Surgery to the abdomen/thorax
- Eye surgery
- An individuals spirometry cannot be included if:
- There is a cough during the first second of the manoeuvre
- A leak at the mouthpiece
- Early termination of manoeuvre
- Sub optimal effort
- They are unable to comprehend the instructions
- Obstruction of the mouthpiece (tongue/teeth)
- Lung volume measurements cannot be included if:
- There is a leak around the mouthpiece
- The patient has a ruptured eardrum
- They are unable to comprehend the instructions
- Obstruction of the mouthpiece (tongue/teeth)
- The patient is on supplementary oxygen and cannot come off it (this must be discontinued for a suitable period prior to nitrogen washout)
- Patients who are CO2 retainers may not be able to undergo nitrogen washout
- The patients test results must meet the acceptability criteria of the ARTP pulmonary function testing statement (updated 2020). For spirometry this states that there must be 3 technically acceptable attempts within 150ml, however, if the the individual has an FVC <1.00L this can be 100ml. Nitrogen washout requires two technically acceptable attempts within 10% (as per trust policy), whereas, for body plethysmography three technically acceptable attempts should be obtained within 5%.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Shrewsbury and Telford hospital Trust
Telford, Shropshire, TF1 6TF
About this study
Official title: Does Severity of Airflow Obstruction Correlate to Static Lung Volumes Obtained by Nitrogen Washout and Body Plethysmography?
Obstructive lung disease is defined by limitations in expiratory airflow, caused by excess mucus, loss of muscle tone, and structural changes. Over time airflow reduction can lead to gas trapping in the lungs (hyperinflation). Hyperinflation is linked to diminished exercise tolerance, shortness of breath, and a poor quality of life. Early treatment options include inhalers and pulmonary rehabilitation; however, surgical intervention and oxygen therapy may be required in the later stages. More prompt, accurate diagnosis will help to improve patient outcomes and optimise their treatment pathways.
Two methodologies used to determine lung volumes and hyperinflation, are nitrogen washout and body plethysmography. The accuracy of each in defining lung volumes in patients with obstructive lung disease is debated in literature. Plethysmography requires the patient to sit in an enclosed box and perform a panting manoeuvre and uses measured changes in volume and pressure to derive lung volumes. Plethysmography has been suggested to overestimate lung volumes in patients with obstructive lung disease. On the other hand, nitrogen washout relies on 'washing out' all the nitrogen from the lungs to calculate lung volumes. Gas trapping and poor airflow circulation that occurs in patients with airflow obstruction may lead to underestimated lung volumes.
This study will aim to investigate if there is a significant difference between lung volumes obtained by both nitrogen washout and body plethysmography in patients with obstructive lung disease. Subjects with mild, moderate, severe, and very severe obstruction, including those with no obstruction for comparison will be included, with approximately 10 from each group. They will be asked if they consent to undergo an extra test during their routine hospital appointment, which will add ~15 minutes to their visit.
Read the detailed description
Obstructive lung disease is defined by limitations in expiratory airflow, caused by excess mucus, loss of muscle tone, and structural changes. Over time airflow reduction can lead to gas trapping in the lungs (hyperinflation). Hyperinflation is linked to diminished exercise tolerance, shortness of breath, and a poor quality of life. Early treatment options include inhalers and pulmonary rehabilitation; however, surgical intervention and oxygen therapy may be required in the later stages. More prompt, accurate diagnosis will help to improve patient outcomes and optimise their treatment pathways.
Two methodologies used to determine lung volumes and hyperinflation, are nitrogen washout and body plethysmography. The accuracy of each in defining lung volumes in patients with obstructive lung disease is debated in literature. Plethysmography requires the patient to sit in an enclosed box and perform a panting manoeuvre and uses measured changes in volume and pressure to derive lung volumes. Plethysmography has been suggested to overestimate lung volumes in patients with obstructive lung disease. On the other hand, nitrogen washout relies on 'washing out' all the nitrogen from the lungs to calculate lung volumes. Gas trapping and poor airflow circulation that occurs in patients with airflow obstruction may lead to underestimated lung volumes.
This study will aim to investigate if there is a significant difference between lung volumes obtained by both nitrogen washout and body plethysmography in patients with obstructive lung disease. Subjects with mild, moderate, severe, and very severe obstruction, including those with no obstruction for comparison will be included, with approximately 10 from each group. They will be asked if they consent to undergo an extra test during their routine hospital appointment, which will add ~15 minutes to their visit.
Expiratory airflow limitation is the hallmark of obstructive pulmonary disease; Parenchymal remodelling, mucous impaction, oedema, and a decrease of smooth muscle tone all contribute to the structural and anatomical changes that occur (O'Donnell, 2006). Individuals with bronchiectasis and chronic obstructive pulmonary disease often have inflammation in their airways (COPD). Impaired mucociliary clearance and increased mucus production are caused by inflammation that occurs inside the airway epithelium. Because of increased connective tissue deposition, the bronchial walls thicken, and the lumen of the airways decrease over time (Hogg, 2004). Airflow obstruction is defined as a reduction in expiratory airflow when compared to the total volume of air exhaled and is investigated by a test called spirometry. The two measurements required to identify obstructive lung disease are FEV1 (forced expiratory volume in the first second of expiration following a maximal inspiration) and FVC (forced vital capacity - the maximal amount of air that can be exhaled forcibly following maximal inhalation). For airflow obstruction to be diagnosed the FEV1/FVC ratio of must be <70%. The FEV1 percent predicted is then used to determine the severity of obstruction following this. Spirometry is commonly used to identify the presence of COPD (chronic obstruction pulmonary disease) or the severity/absence of obstruction in diseases such as asthma (Eschenbacher, 2016). TLC (total lung capacity) describes the amount of air in the lungs at maximal inspiration, the expected amount is determined by height, age, weight, ethnicity and gender. Chest wall deformities, tumours, level of physical activity and the presence of respiratory disease can all alter an individual's TLC.
Often, as a result of chronic obstructive lung disease, hyperinflation occurs which is the abnormal increase in FRC. This is caused by the imbalance between the reduction in airflow from the lungs compared to the total volume of the lungs. Changes in elastic properties of the lungs and impaired inspiratory muscle function also contribute to the extent of hyperinflation over time (Gibson, 1996). Hyperinflation is associated with reduced exercise capacity, dyspnoea and reduced quality of life. Individuals with COPD were found to spend 1/3 of the day standing/walking compared to healthy individuals of the same age who spent around ½ of the day doing so; such physical deconditioning significantly accelerates disease progression (Cooper, 2009). Treatment and intervention that targets hyperinflation can improve not only respiratory symptoms but also metabolic parameters and chronic inflammation. Pulmonary rehabilitation, bronchodilators and oxygen therapy are often utilised, however, surgical intervention such as lung volume reduction surgery (LVRS) is believed to provide the most benefit (Criner, 2017). The accuracy of lung volume measurements is vital to determine if interventional treatment (e.g., bronchodilators, LVRS, supplemental oxygen) have been successful or if a patient needs surgical intervention.
Methods including body plethysmography, nitrogen washout, helium dilution, and the more novel radiographic method utilising computed tomography (CT) are used by clinicians to calculate lung volumes. They produce measurements comprising FRC (functional residual capacity), IC (inspiratory capacity), and VC (vital capacity) which are used to calculate TLC (Delgado, 2019). Figure 1 gives a schematic of how these values relate to each other. The two methods that are investigated in this research project are nitrogen washout and body plethysmography. Nitrogen washout is a gas dilution technique that involves the patient breathing 100% oxygen through a mouthpiece to remove the nitrogen from the lungs. The mouthpiece has a two-way valve allowing the patient to breathe in oxygen whilst exhale through a pneumotach that measures the concentration of nitrogen in the exhaled air until it reaches <1.5% (Wanger, 2005). Body plethysmography measures pressure variations in a chamber with a constant temperature and volume. The patient must perform several breathing manoeuvres, including tidal breathing and panting, through a pneumotach inside an air-tight chamber. Chest wall collapse and expansion alters the pressure within the chamber, this is measured by transducers and allows lung volume measurements to be taken (Delgado, 2019).
There has long been debate over the accuracy of lung volume measurement techniques, Garfield et al stated that body plethysmography overestimates lung volumes in patients with airway obstruction in comparison to CT (Garfield, 2012). Lufti et al more recently stated in their research gas dilution techniques like nitrogen washout may underestimate TLC in patients with obstructive lung disease (Lutfi, 2017). One case study looking at lung volumes in a single patient with obstructive lung disease suggested that plethysmography may falsely elevate lung volume measurements due to airway resistance and mouth compliance, whereas nitrogen washout might underestimate volumes due to non-communicative areas of the lungs (Sue, 2013). On the other hand, another study found, when comparing lung volumes derived from CT to body plethysmography and helium dilution, in patients with obstructive lung disease, there was a significant difference between CT and helium dilution but not CT and body plethysmography (O'Donnell CR, 2010), suggesting plethysmography was the more accurate of the two. As helium dilution and nitrogen washout both rely on gases mixing to determine lung volumes, perhaps similar results may be seen if this was repeated using nitrogen washout. To the researcher's knowledge there has not been a comparison between lung volumes obtained via nitrogen washout and body plethysmography in patients with varying severities of obstructive lung disease. If a significant difference is found between the methods, this could aid in choosing the most appropriate and accurate lung volume measurement tool in patients with obstructive lung disease. Such findings may shorten appointment times, improve patient treatment pathways and reduce monetary costs to the hospital. COPD costs the NHS approximately 1.9 billion a year, earlier intervention and treatment may help to reduce this burden (The_Lancet, 2018).
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Being tested
- Physiological test
- Keywords
- airflow obstruction, plethysmography, lung volumes
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physiological testOther
Lung volume measurements will be obtained using nitrogen washout and body plethysmography
| Study group | Role | What they receive |
|---|---|---|
| Obtaining lung volume measurements in patients with airflow obstruction | Other | All patients involved in this study will be attending a pulmonary function test as part of their routine patient treatment pathway, requested by their consultant. Potential participants will be sent a patient information sheet prior to their lung function test.
The pulmonary function test begins routinely, with the pre-test questions. Spirometry will then be performed. If the patient's results are variable and the repeatability criteria are not met, the patient will not be asked to take part in the study, and no additional tests (not requested by the consultant routinely) will be carried out. If the patient has normal or obstructive results (FEV1/FVC <70%) the patient will sign the consent form and both lung volume tests will be conducted. They must be able to follow the instructions for both nitrogen washout and body plethysmography, and the results must also meet the acceptability and repeatability criteria. Receives: Other: Physiological test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of lung volumes by two routine techniques in patients referred for pulmonary function testing.
Patients referred for pulmonary function test as part of their routine patient treatment pathway will have lung volumes measured by nitrogen washout and body plethysmography, which are both routine techniques. Participants will have a range of obstructive or normal lung function. When the test is finished, patients will be told that their test results will be sent to their consultant, who will then explain them at a follow up appointment/ phone call (this is routine procedure).
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2022
- Study start16 Mar 2023
- Primary completion28 Apr 2023
- Study completion31 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Virginia Hawkins
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Virginia Hawkins, Manchester Metropolitan University
- Investigators
- Nicholas John, Principal investigator, Shrewsbury and Telford Hospital Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05616780
- Sponsor's protocol ID
- 46246
- Status last verified
- Mar 2024
- First submitted
- 8 Nov 2022
- Last updated
- 29 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Severity of Airflow Obstruction Correlate to Static Lung Volumes Obtained by Nitrogen Washout and Body Plethysmography?
- ClinicalTrials.gov ID
- NCT05616780
- Acronym / sponsor ID
- 46246
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Keywords
- airflow obstruction, plethysmography, lung volumes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Virginia HawkinsUniversity, hospital or other
- Study start
- 16 Mar 2023 (actual)
- Primary completion
- 28 Apr 2023 (actual)
- Study completion
- 31 May 2023 (actual)
- First posted
- 15 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obstructive lung disease is defined by limitations in expiratory airflow, caused by excess mucus, loss of muscle tone, and structural changes. Over time airflow reduction can lead to gas trapping in the lungs (hyperinflation). Hyperinflation is linked to diminished exercise tolerance, shortness of breath, and a poor quality of life. Early treatment options include inhalers and pulmonary rehabilitation; however, surgical intervention and oxygen therapy may be required in the later stages. More prompt, accurate diagnosis will help to improve patient outcomes and optimise their treatment pathways.
Two methodologies used to determine lung volumes and hyperinflation, are nitrogen washout and body plethysmography. The accuracy of each in defining lung volumes in patients with obstructive lung disease is debated in literature. Plethysmography requires the patient to sit in an enclosed box and perform a panting manoeuvre and uses measured changes in volume and pressure to derive lung volumes. Plethysmography has been suggested to overestimate lung volumes in patients with obstructive lung disease. On the other hand, nitrogen washout relies on 'washing out' all the nitrogen from the lungs to calculate lung volumes. Gas trapping and poor airflow circulation that occurs in patients with airflow obstruction may lead to underestimated lung volumes.
This study will aim to investigate if there is a significant difference between lung volumes obtained by both nitrogen washout and body plethysmography in patients with obstructive lung disease. Subjects with mild, moderate, severe, and very severe obstruction, including those with no obstruction for comparison will be included, with approximately 10 from each group. They will be asked if they consent to undergo an extra test during their routine hospital appointment, which will add ~15 minutes to their visit.
Detailed description
Obstructive lung disease is defined by limitations in expiratory airflow, caused by excess mucus, loss of muscle tone, and structural changes. Over time airflow reduction can lead to gas trapping in the lungs (hyperinflation). Hyperinflation is linked to diminished exercise tolerance, shortness of breath, and a poor quality of life. Early treatment options include inhalers and pulmonary rehabilitation; however, surgical intervention and oxygen therapy may be required in the later stages. More prompt, accurate diagnosis will help to improve patient outcomes and optimise their treatment pathways.
Two methodologies used to determine lung volumes and hyperinflation, are nitrogen washout and body plethysmography. The accuracy of each in defining lung volumes in patients with obstructive lung disease is debated in literature. Plethysmography requires the patient to sit in an enclosed box and perform a panting manoeuvre and uses measured changes in volume and pressure to derive lung volumes. Plethysmography has been suggested to overestimate lung volumes in patients with obstructive lung disease. On the other hand, nitrogen washout relies on 'washing out' all the nitrogen from the lungs to calculate lung volumes. Gas trapping and poor airflow circulation that occurs in patients with airflow obstruction may lead to underestimated lung volumes.
This study will aim to investigate if there is a significant difference between lung volumes obtained by both nitrogen washout and body plethysmography in patients with obstructive lung disease. Subjects with mild, moderate, severe, and very severe obstruction, including those with no obstruction for comparison will be included, with approximately 10 from each group. They will be asked if they consent to undergo an extra test during their routine hospital appointment, which will add ~15 minutes to their visit.
Expiratory airflow limitation is the hallmark of obstructive pulmonary disease; Parenchymal remodelling, mucous impaction, oedema, and a decrease of smooth muscle tone all contribute to the structural and anatomical changes that occur (O'Donnell, 2006). Individuals with bronchiectasis and chronic obstructive pulmonary disease often have inflammation in their airways (COPD). Impaired mucociliary clearance and increased mucus production are caused by inflammation that occurs inside the airway epithelium. Because of increased connective tissue deposition, the bronchial walls thicken, and the lumen of the airways decrease over time (Hogg, 2004). Airflow obstruction is defined as a reduction in expiratory airflow when compared to the total volume of air exhaled and is investigated by a test called spirometry. The two measurements required to identify obstructive lung disease are FEV1 (forced expiratory volume in the first second of expiration following a maximal inspiration) and FVC (forced vital capacity - the maximal amount of air that can be exhaled forcibly following maximal inhalation). For airflow obstruction to be diagnosed the FEV1/FVC ratio of must be <70%. The FEV1 percent predicted is then used to determine the severity of obstruction following this. Spirometry is commonly used to identify the presence of COPD (chronic obstruction pulmonary disease) or the severity/absence of obstruction in diseases such as asthma (Eschenbacher, 2016). TLC (total lung capacity) describes the amount of air in the lungs at maximal inspiration, the expected amount is determined by height, age, weight, ethnicity and gender. Chest wall deformities, tumours, level of physical activity and the presence of respiratory disease can all alter an individual's TLC.
Often, as a result of chronic obstructive lung disease, hyperinflation occurs which is the abnormal increase in FRC. This is caused by the imbalance between the reduction in airflow from the lungs compared to the total volume of the lungs. Changes in elastic properties of the lungs and impaired inspiratory muscle function also contribute to the extent of hyperinflation over time (Gibson, 1996). Hyperinflation is associated with reduced exercise capacity, dyspnoea and reduced quality of life. Individuals with COPD were found to spend 1/3 of the day standing/walking compared to healthy individuals of the same age who spent around ½ of the day doing so; such physical deconditioning significantly accelerates disease progression (Cooper, 2009). Treatment and intervention that targets hyperinflation can improve not only respiratory symptoms but also metabolic parameters and chronic inflammation. Pulmonary rehabilitation, bronchodilators and oxygen therapy are often utilised, however, surgical intervention such as lung volume reduction surgery (LVRS) is believed to provide the most benefit (Criner, 2017). The accuracy of lung volume measurements is vital to determine if interventional treatment (e.g., bronchodilators, LVRS, supplemental oxygen) have been successful or if a patient needs surgical intervention.
Methods including body plethysmography, nitrogen washout, helium dilution, and the more novel radiographic method utilising computed tomography (CT) are used by clinicians to calculate lung volumes. They produce measurements comprising FRC (functional residual capacity), IC (inspiratory capacity), and VC (vital capacity) which are used to calculate TLC (Delgado, 2019). Figure 1 gives a schematic of how these values relate to each other. The two methods that are investigated in this research project are nitrogen washout and body plethysmography. Nitrogen washout is a gas dilution technique that involves the patient breathing 100% oxygen through a mouthpiece to remove the nitrogen from the lungs. The mouthpiece has a two-way valve allowing the patient to breathe in oxygen whilst exhale through a pneumotach that measures the concentration of nitrogen in the exhaled air until it reaches <1.5% (Wanger, 2005). Body plethysmography measures pressure variations in a chamber with a constant temperature and volume. The patient must perform several breathing manoeuvres, including tidal breathing and panting, through a pneumotach inside an air-tight chamber. Chest wall collapse and expansion alters the pressure within the chamber, this is measured by transducers and allows lung volume measurements to be taken (Delgado, 2019).
There has long been debate over the accuracy of lung volume measurement techniques, Garfield et al stated that body plethysmography overestimates lung volumes in patients with airway obstruction in comparison to CT (Garfield, 2012). Lufti et al more recently stated in their research gas dilution techniques like nitrogen washout may underestimate TLC in patients with obstructive lung disease (Lutfi, 2017). One case study looking at lung volumes in a single patient with obstructive lung disease suggested that plethysmography may falsely elevate lung volume measurements due to airway resistance and mouth compliance, whereas nitrogen washout might underestimate volumes due to non-communicative areas of the lungs (Sue, 2013). On the other hand, another study found, when comparing lung volumes derived from CT to body plethysmography and helium dilution, in patients with obstructive lung disease, there was a significant difference between CT and helium dilution but not CT and body plethysmography (O'Donnell CR, 2010), suggesting plethysmography was the more accurate of the two. As helium dilution and nitrogen washout both rely on gases mixing to determine lung volumes, perhaps similar results may be seen if this was repeated using nitrogen washout. To the researcher's knowledge there has not been a comparison between lung volumes obtained via nitrogen washout and body plethysmography in patients with varying severities of obstructive lung disease. If a significant difference is found between the methods, this could aid in choosing the most appropriate and accurate lung volume measurement tool in patients with obstructive lung disease. Such findings may shorten appointment times, improve patient treatment pathways and reduce monetary costs to the hospital. COPD costs the NHS approximately 1.9 billion a year, earlier intervention and treatment may help to reduce this burden (The_Lancet, 2018).
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Obtaining lung volume measurements in patients with airflow obstruction | Other | Other: Physiological testAll patients involved in this study will be attending a pulmonary function test as part of their routine patient treatment pathway, requested by their consultant. Potential participants will be sent a patient information sheet prior to their lung function test. The pulmonary function test begins routinely, with the pre-test questions. Spirometry will then be performed. If the patient's results are variable and the repeatability criteria are not met, the patient will not be asked to take part in the study, and no additional tests (not requested by the consultant routinely) will be carried out. If the patient has normal or obstructive results (FEV1/FVC <70%) the patient will sign the consent form and both lung volume tests will be conducted. They must be able to follow the instructions for both nitrogen washout and body plethysmography, and the results must also meet the acceptability and repeatability criteria. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- A minimum of 10 patients from each group will be included; normal lung function/ no airflow obstruction (FEV1/FVC >70%), mild airflow obstruction (FEV1/FVC <70% and FEV1 >80% predicted), moderate airflow obstruction (FEV1/FVC <70% and FEV1 50-80% predicted), severe airflow obstruction (FEV1/FVC <70% and FEV1 30-50% predicted) and very severe (FEV1/FVC <70% and FEV1 >30% predicted).
- Al patients will be over the age of 18 with no upper age limit. No children will be included in this study.
- Patients must have withheld their inhalers.
Key exclusion criteria (23 listed)
- [15:10] Jessica Armstrong
- Heart attack
- Stroke
- Haemoptysis
- Pneumothorax
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physiological testLung volume measurements will be obtained using nitrogen washout and body plethysmography | Other | Obtaining lung volume measurements in patients with airflow obstruction |
Primary outcome
Measurement of lung volumes by two routine techniques in patients referred for pulmonary function testing.
Time frame: 6 months
Patients referred for pulmonary function test as part of their routine patient treatment pathway will have lung volumes measured by nitrogen washout and body plethysmography, which are both routine techniques. Participants will have a range of obstructive or normal lung function. When the test is finished, patients will be told that their test results will be sent to their consultant, who will then explain them at a follow up appointment/ phone call (this is routine procedure).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2024.
- Individual participant dataSharing planned: No
Related trials for Pulmonary Disease, Chronic Obstructive
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicholas John principal investigator
Shrewsbury and Telford Hospital Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physiological test in people with Pulmonary Disease, Chronic Obstructive, run by Virginia Hawkins at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of lung volumes by two routine techniques in patients referred for pulmonary function testing. (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2024.